【摘要】 目的:评价文拉法辛与帕罗西汀治疗首发抑郁症的疗效、生存质量与不良反应。方法:106例首发抑郁症患者随机平分为文拉法辛组和帕罗西汀组,每组53例。两组分别给予文拉法辛与帕罗西汀治疗,疗程8周。采用汉密尔顿抑郁量表(HAMD)、健康状况问卷(SF-36)及治疗中出现的症状量表(TESS)评定疗效、生存质量及不良反应。结果:治疗后两组HAMD评分均较治疗前有显著降低(P<0.01);治疗2周,以文拉法辛组显著较低(P<0.01);两组中的重度抑郁患者(HAMD>24分)治疗后HAMD评分仍以文拉法辛组显著为低(P<0.01);治疗8周,两组SF-36总分及各因子分均显著高于治疗前(P<0.01);但两组间比较差异无统计学意义(P>0.05)。结论:文拉法辛能显著改善患者的生存质量,起效快,对重度抑郁症的疗效明显。更多还原

【Abstract】 Objective:To evaluate therapeutic effect,quality of life and adverse effect of venlafaxine and paroxetine in the treatment of first-episode depression.Method:106 patients with first-episode depression were randomly divided into two groups for an 8-week treatment with venlafaxine or paroxetine.Hamilton rating scale of depression(HAMD),short form 36 health survey questionnaire(SF-36) and treatment emergent symptom scale(TESS) were performed to assess the treatment effects,life quality and adverse effects.Results:The score of HAMD in venlafaxine group was significantly lower than that in paroxetine group after 2-week treatment(P < 0.05),although both of them significantly declined(P < 0.01).After 8 weeks treatment,the scores of SF-36 have significantly increased(P <0.01),but they have no significant differences between two groups(P > 0.05).Conclusion:Venlafaxine is an effective antidepressant in improvement of life quality quickly and specially in the treatment of major depressive disorders.更多还原